Back to Results
First PageMeta Content
Insider trading / Business / Crime / Economics / Corporate crime / Samuel D. Waksal / Cetuximab / SEC Rule 10b-5 / Securities fraud / Corruption / Eli Lilly and Company / ImClone Systems


indictment - securities fraud
Add to Reading List

Document Date: 2010-02-04 21:15:59

Open Document

File Size: 196,08 KB

Share Result on Facebook

City

NEW YORK / /

Company

UBS / ImClone Systems Incorporated / Inside Information 6 / Insider Trading / Roth Capital Partners LLC / /

Country

United States / /

Currency

USD / /

Event

FDA Phase / M&A / /

IndustryTerm

treatment for irinotecan refractory colorectal cancer / manipulative and deceptive devices / /

Organization

Grand Jury / ImClone’s office of the General / National Association of Securities Dealers / United States Food and Drug Administration / /

Person

SAMUEL WAKSAL / /

Position

Counsel / president / chief executive officer / and a director / executive vice-president and chief operating officer / officer and director / /

Product

Erbitux / FDA / /

ProvinceOrState

Delaware / New York / /

PublishedMedium

the FDA review / /

SocialTag